Reduced growth hormone secretion improves insulin sensitivity in adolescent girls with type 1 diabetes

Acta Paediatrica, International Journal of Paediatrics

Volumn 85, Issue 1, 1996, Pages 31-37

  Aman J ^a   Kroon, M ^a   Karlsson, I ^a   Jones, I ^a   Hagenas L ^b  

^a ÖREBRO MEDICAL CENTRE HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Anticholinergic treatment; Diabetes mellitus; Growth hormone; Insulin resistance; Insulin dependence; Puberty

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; GROWTH HORMONE; INSULIN; PIRENZEPINE;

ADOLESCENT; ARTICLE; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; DIABETES MELLITUS; DRUG EFFECT; FEMALE; GLUCOSE CLAMP TECHNIQUE; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE RELEASE; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0030024849     PISSN: 08035253     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1651-2227.1996.tb13886.x     Document Type: Article

References (30)

1. Amiel SA, Sherwin RS, Simonson DC, Lauritano AA, Tamborlane WV. Impaired insulin action in puberty. A contributing factor to poor glycemic control in adolescents with diabetes. N Engl J Med 1986;315:215-9
2. Amiel SA, Caprio S, Sherwin RS, Plewe G, Haymond MW, Tamborlane WV. Insulin resistance of puberty: a defect restricted to peripheral glucose metabolism. J Clin Endocrinol Metab 1991;72:277-82
3. Bloch CA, Clemons P, Sperling MA. Puberty decreases insulin sensitivity. J Pediatr 1987;110:481-7
4. Smith CP, Archibald HR, Thomas JM, Tarn AC, Williams AJ, Gale EA, et al. Basal and stimulated insulin levels rise with advancing puberty. Clin Endocrinol (Oxf) 1988;28:7-14
5. Johansen K, Hansen AP. Diurnal growth hormone levels in poorly and well controlled juvenile diabetics. Diabetes 1971;20:239-45
6. Press M, Tamborlane WV, Sherwin RS. Importance of raised growth hormone levels in mediating the metabolic derangements of diabetes. N Engl J Med 1984;310:810-5
7. Edge JA, Dunger DB, Matthews DR, Gilbert JP, Smith CP. Increased overnight growth hormone concentrations in diabetic compared with normal adolescents. J Clin Endocrinol Metab 1990;71:1356-62
8. Campbell PJ, Bolli GB, Gerich JE. Prevention of the dawn phenomonon (early morning hyperglycemia) in insulin-dependent diabetes mellitus by bedtime intranasal administration of long-acting somatostatin analog. Metabolism 1988;37:34-7
9. Taylor BJ, Smith PJ, Brook CGD. Inhibition of physiological growth hormone secretion by atropine. Clin Endocrinol 1985;22:497-501
10. Evans PJ, Dieguez C, Foord S, Peters RJ, Hall R, Scanlon MF. The effects of cholinergic blockade on the growth hormone and prolactin response to insulin hypoglycaemia. Clin Endocrinol (Oxf) 1985;22:733-7
11. Peters JR, Evans PJ, Page MD, Hall R, Gibbs JT, Dieguez C, Scanlon MF. Cholinergic muscarinic receptor blockade with pirenzepine abolishes slow wave sleep-related growth hormone release in normal adult males Clin Endocrinol (Oxf) 1986;25:213-7
12. Page MD, Bevan JS, Dieguez C, Peters JR, Scanlon MF. Cholinergic blockade with pirenzepine improves carbohydrate tolerance and abolishes the GH responses to meals in normal subjects. Clin Endocrinol (Oxf)1989;30:519-24
13. Atiea J, Creagh F, Page M, Owens DR, Scanlon MF, Peters JR. Early morning hyperglycemia in IDDM. Acute effects of cholinergic blockade. Diabetes Care 1989;12:443-8
14. Martina V, Maccario M, Tagliabue M, Corno M, Camanni F. Chronic treatment with pirenzepine decreases growth hormone secretion in insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1989;68:392-6
15. Ara J, Kang S, Creagh FM, Scanlon MF, Peters JR. Modulation of glucose and growth hormone responses to meals and exercise in type 1 diabetes by cholinergic muscarinic blockade Diabet Med 1994;11:92-7
16. Edge JA, Matthews DR, Dunger DB. The dawn phenomenon is related to overnight growth hormone release in adolescent diabetics. Clin Endocrinol (Oxf) 1990;33:729-37
17. De Fronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979;237:E214-23
18. Bang P, Eriksson U, Sara V, Wivall I L, Hall K. Comparison of acid ethanol extraction and acid gel filtration prior to IGF-I and IGF-II radioimmunoassays: improvement of determinations in acid ethanol extracts by the use of truncated IGF-I as radioligand. Acta Endocrinol (Copenh) 1991;124:620-9
19. Povoa G, Roovete A, Hall K. Cross-reaction of serum somatomedin-binding protein in a radioimmunoassay developed for somatomedin-binding protein isolated from human amniotic fluid. Acta Endocrinol (Copenh) 1984;107:563-70
20. Aman J, Jones I. Urinary growth hormone determination in prepubertal children using a modification of a commercial kit designed for determination of growth hormone in serum. Scand J Clin Lab Invest 1994;54:227-33
21. Edge JA, Matthews DR, Dunger DB. Failure of current insulin regimes to meet the overnight insulin requirements of adolescents with insulin-dependent diabetes. Diabetes Res 1990;15:109-12
22. Amiel SA, Sherwin RS, Hintz RL, Gartner JM, Press CM, Tamborlane WV. Effect of diabetes and its control on insulin-like growth factors in the young subject with type 1 diabetes. Diabetes 1984;33:1175-9
23. Baxter RC, Bryon JM, Turtle JR. Somatogenic receptors of rat liver; regulation by insulin. Endocrinology 1980;107:1176-81
24. Taylor AM, Dunger DB, Grant DB. Somatomedin-C/IGF-I measured by radioimmunoassay and somatomedin bioactivity in adolescents with insulin-dependent diabetes compared with puberty-matched controls. Diabetes Res 1988;9:177-81
25. Taylor AM, Dunger DB, Preece MA Holly JM, Smith CP, Wass JA, et al. The growth hormone-independent insulin-like growth factor-I binding protein BP-28 is associated with serum insulin-like growth factor -Iinhibitory bioactivity in adolescent insulin-dependent diabetics. Clin Endocrinol (Oxf). 1990;32:229-39
26. Richardson SB, Hollander CS, D1/2AEletto R, Greenleaf PW, Thaw C. Acetylcholine inhibits the release of somatostatin from rat hypothalamus in vitro. Endocrinology 1980;107:122-9
27. Baxter RC, Cowel CT. Diurnal rhythm of growth hormone-independent binding protein for insulin-like growth factors in human plasma. J Clin Endocrinol Metab 1987;65:432-40
28. Batch JA, Baxter RC, Werther G. Abnormal regulation of insulin-like growth factor binding proteins in adolescents with insulin-dependent diabetes. J Clin Endocrinol Metab 1991;73:964-8
29. Holly JM, Dunger DB, Edge JA, Smith CP, Chard T, Wass JA. Insulin-like growth factor binding protein-1 levels in diabetic adolescents and their relationship to metabolic control. Diabet Med 1990;7:618-23
30. Campbell PJ, Bolli GB, Cryer PE, Gerich JE. Pathogenesis of the dawn phenomenon in patients with insulin-dependent diabetes mellitus. Accelerated glucose production and impaired glucose utilization due to nocturnal surges in growth hormone secretion. N Engl J Med 1985;312:1473-9